Why it was recalled
Superpotent Drug.
Product description
Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01
Lot numbers, UPCs & expiration codes
Lot #:18A18, Exp. 01/2020
Where it was sold
Nationwide within the United States
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0339-2019
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- Dec 6, 2018
- FDA report date
- Dec 26, 2018
- Quantity
- 1996 bottles
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Pfizer Inc.
Original FDA data
Every field from FDA enforcement report D-0339-2019, exactly as published.
Show all FDA fields
- City
- New York
- State
- NY
- Status
- Terminated
- Country
- United States
- Event ID
- 81731
- Address
- 235 E 42nd St
- Code information
- Lot #:18A18, Exp. 01/2020
- Postal code
- 10017-5703
- Report date
- Dec 26, 2018
- Product type
- Drugs
- Recall number
- D-0339-2019
- Classification
- Class II
- Recalling firm
- Pfizer Inc.
- Product quantity
- 1996 bottles
- Termination date
- Oct 8, 2020
- Reason for recall
- Superpotent Drug.
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle, Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01
- Distribution pattern
- Nationwide within the United States
- Recall initiation date
- Dec 6, 2018
- Initial firm notification
- Letter
- Center classification date
- Dec 18, 2018